Preclinical in vitro models from genetically engineered mice for breast and colon cancer (review)

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1195-1201

  Telang, Nitin ^a   Katdare, Meena ^b  

^a Palindrome Liaisons   (United States)

^b HAMPTON UNIVERSITY   (United States)

Author keywords

Cancer risk; Genetically altered epithelial cells

Indexed keywords

APC PROTEIN; EFLORNITHINE; FENRETINIDE; PROTEIN MLH1; SULINDAC; TAMOXIFEN; TUMOR MARKER;

ANCHORAGE INDEPENDENT GROWTH; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CELL CYCLE PROGRESSION; COLON CANCER; CYTOSTASIS; DRUG SCREENING; IN VITRO STUDY; NONHUMAN; ONCOGENE MYC; ONCOGENE RAS; PHYTOCHEMISTRY; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICE, TRANSGENIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79953037479     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1215     Document Type: Review

References (42)

1. Jemal AR, Segal R, Ward E, et al: Cancer Statistics. Cancer J Clin 58: 71-96, 2008.
2. Martin AM and Weber B: Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 92: 1126-1135, 2000.
3. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
4. Fodde R, Smits R and Clevers H: APC signal transduction and genetic instability in colon cancer. Nat Rev Cancer 1: 55-67, 2001. (Pubitemid 33741881)
5. Stewart TA, Pattengale PK and Leder P: Spontaneous mammary adenocarcinoma in transgenic mice that carry and express MTV/ myc fusion genes. Cell 38: 627-637, 1984. (Pubitemid 15176093)
6. Fodde R, Edelmann W, Yang K, et al: A targeted chain termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 91: 8969-8973, 1994.
7. Su LK, Kinzler KW, Vogelstein B, et al: Multiple intestinal neoplasia caused by a mutation in the murine homologue of the APC gene. Science 256: 668-670, 1992.
8. 1/1638N mice. Cancer Res 59: 1301-1307, 1999.
9. Fisher B, Constantino JP, Wickerman DL, et al: Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project (NSABP P-1) study. J Natl Cancer Inst 90: 1371-1388, 1998. (Pubitemid 28439961)
10. Paik S, Bryant J, Park C, et al: ErbB-2 and response to Doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998. (Pubitemid 28439960)
11. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy of operable HER-2 positive breast cancer. N Engl J Med 353: 1673-1684, 2005. (Pubitemid 41464706)
12. Cuzik J, Powels T, Veronesi U, et al: Overview of main outcomes of breast cancer prevention trials. Lancet 361: 296-300, 2003. (Pubitemid 36126189)
13. Abbruzzese JL and Lippman SM: The convergence of cancer prevention and therapy in early phase clinical drug development. Cancer Cell 6: 321-326, 2004. (Pubitemid 39361433)
14. Solomon SD, McMurrray JJV, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080, 2005. (Pubitemid 40365348)
15. Frese KK and Tuveson DA: Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658, 2007. (Pubitemid 47327410)
16. Abate-Shen C, Brown PH, Colburn NH, et al: The un-taped potential of genetically engineered mouse models in chemoprevention research: Opportunities and challenges. Cancer Prev Res 1: 161-166, 2008.
17. Allred CD, O'Connell P and Fuqua SAW: Biomarkers in early breast neoplasia. J Cell Biochem 17: 125-131, 1993.
18. O'Shauhnessy JA, Kelloff GJ, Gorden GB, et al: Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin Cancer Res 8: 314-346, 2002.
19. Kelloff GJ, Lippman SM, Dannenberg AJ, et al: Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer, a plan to move forward. Qin Cancer Res 22: 3661-3697, 2006. (Pubitemid 44000248)
20. Telang NT, Narayanan R, Bradlow HL, et al: Coordinated expression of interme diate biomarkers for tumorigenic transformation in Ras-transfected mouse mammary epithelial cells. Breast Cancer Res Treat 18: 155-163, 1991.
21. Telang NT, Osborne MP, Sweterlitsch LA, et al: Neoplastic transformation of mouse mammary epithelial cells by deregulated c-myc expression. Cell Regulation 1: 863-872, 1990.
22. Zhai YF, Beittenmiller H, Wang B, et al: Increased expression of specific tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res 53: 2272-2278, 1993. (Pubitemid 23156812)
23. Telang N and Katdare M: Combinatorial prevention of carcinogenic risk in a model for familial colon cancer. Oncol Rep 17: 909-914, 2007.
24. Telang N and Katdare M: Novel cell culture model for prevention of carcinogenic risk in familial adenomatous polyposis syndrome. Oncol Rep 21: 1017-1021, 2009.
25. Katdare M, Kopelovich L and Telang N: Efficacy of chemopreventive agents on growth inhibition of Ape [+/-] 1638N COL colonic epithelial cells. Int J Mol Med 10: 427-432, 2002.
26. Telang NT, Li G and Katdare M: Prevention of early onset familial/hereditary colon cancer: New models and biomarkers (Review). Int J Oncol 28: 1523-1529, 2006.
27. Subbaramaiah K, Chung WJ, Michaluart P, et al: Resveratrol inhibits cyclo-oxygenase-2 transcription and activity in phorbol ester treated human mammary epithelial cells. J Biol Chem 273: 21875-21882, 1998. (Pubitemid 28405365)
28. Jinno H, Steiner MG, Nason-Burchenal K, et al: Preventive efficacy of receptor class selective retinoids on HER-2 oncogene expressing preneoplastic human mammary epithelial cells. Int J Oncol 21: 127-134, 2002.
29. Katdare M, Osborne MP and Telang NT: Soy isoflavone genestein modulates cell cycle progression and induces apoptosis in HER-2/ neu oncogene expressing human breast epithelial cells. Int J Oncol 21: 809-816, 2002.
30. Katdare M, Osborne MP and Telang NT Novel cell culture models for prevention of human breast cancer (Review). Int J Oncol 22: 509-515, 2003.
31. Veronesi U, DePalo G, Costa A, et al: Chemoprevention of breast cancer with retinoids. J Natl Cancer Inst 12: 93-97, 1992.
32. Giardiello FM, Hamilton SR, Krush AH, et al: Treatment of colonic and rectal adenoma with Sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993. (Pubitemid 23131373)
33. Gerner EW and Meyskens FL: Polyamines and cancer: Old molecules, new understanding. Nat Rev Cancer 4: 785-792, 2004.
34. Meyskens FL, McLaren CE, Petot D, et al: Difluoro-methylomithine plus Sulndac for prevention of sporadic colorectal adenomas: a randomized placebo controlled double blind trial. Cancer Prev Res 1: 32-38, 2008.
35. Jacoby RF, Cole CE, Tutsch K, et al: Chemopreventive efficacy of combined Piroxicam and Difluoro-methylomithine on Apc mutant mouse adenoma and selective toxicity against mutant embryos. Cancer Res 60: 1864-1870, 2000.
36. Swamy MV, Patlolla JMR, Steele VE, et al: Chemoprevention of familial adenomatous polyposis by low doses of Atorvastatin and Celecoxib individually and in combination to ApcMin mice. Cancer Res 66: 7370-7377, 2006. (Pubitemid 44197721)
37. Dean M, Fojo T and Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005. (Pubitemid 40488633)
38. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
39. Moore KA and Lemishka IR: Stem cells and their niches. Science 311: 1880-1885, 2006.
40. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007
41. Rausch V, Liu I, Kallifatidis G, et al: Synergistic activity of Sorafenib and Sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 70: 5004-5013, 2010.
42. Telang N and Katdare M: Breast and colon cell lines from genetically engineered mice: Novel in vitro models for carcinogenesis and cancer prevention. Int J Mol Med 24: S17, 2009.